(Reuters) - Bristol-Myers Squibb Co said on Tuesday the U.S. Food and Drug Administration had approved a four-week dosing schedule for its cancer drug, Opdivo.
Original Article: FDA approves new dosing for Bristol-Myers Squibb's Opdivo
